Joseph Chiu
Overview
Explore the profile of Joseph Chiu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
2061
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stern N, Green S, Thaker N, Krout D, Chiu J
J Food Prot
. 2019 Apr;
47(5):372-374.
PMID: 30934414
Approximately 800 fresh and frozen meat and poultry samples collected at the point of slaughter were analyzed for Campylobacter jejuni . C. jejuni and C. coli isolates were never discriminated....
2.
Robb M, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al.
Lancet Infect Dis
. 2012 Jun;
12(7):531-7.
PMID: 22652344
Background: The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did not...
3.
Pitisuttithum P, Rerks-Ngarm S, Chiu J, Kim J, Benenson M, Kent S, et al.
Southeast Asian J Trop Med Public Health
. 2012 Feb;
42(5):1130-46.
PMID: 22299439
HIV/AIDS is a major public health problem worldwide, especially in developing countries. The development of a safe and effective HIV vaccine is central to stopping the epidemic and would be...
4.
Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, et al.
PLoS One
. 2011 Dec;
6(12):e27837.
PMID: 22205930
Background: A prime-boost vaccination regimen with ALVAC-HIV (vCP1521) administered intramuscularly at 0, 4, 12, and 24 weeks and gp120 AIDSVAX B/E at 12 and 24 weeks demonstrated modest efficacy of...
5.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al.
N Engl J Med
. 2009 Oct;
361(23):2209-20.
PMID: 19843557
Background: The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. Methods: In a community-based, randomized, multicenter, double-blind, placebo-controlled...
6.
Evans T, Frey S, Israel H, Chiu J, El-Habib R, Gilbert P, et al.
Vaccine
. 2004 Jun;
22(20):2626-30.
PMID: 15193388
The efficacy and practical application of human immunodeficiency virus type 1 (HIV-1) vaccines may depend in part on the longevity of the immune responses generated, particularly those in the memory...
7.
Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, Brown A, et al.
J Acquir Immune Defic Syndr
. 2004 Apr;
36(1):622-9.
PMID: 15097306
The natural history and progression of HIV-1 infection in Thailand and other developing countries in Asia and Africa have not been well defined. Nevertheless, valid data are needed to evaluate...
8.
Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J, de Souza M, et al.
J Infect Dis
. 2003 Jul;
188(2):219-27.
PMID: 12854076
Safety and immunogenicity of 2 recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein (gp) 120 vaccines derived from SF2 (subtype B) and CM235 (CRF01_AE, Thai E) were evaluated in...
9.
Thapinta D, Jenkins R, Morgan P, Chiu J, Boenim W, Bussaratid V, et al.
J Acquir Immune Defic Syndr
. 2002 Aug;
30(5):503-13.
PMID: 12154341
Factors believed to be predictive of retention through the recruitment and screening processes for preventive HIV trials were investigated in a large multisite phase I/II HIV vaccine trial in Thailand....